NEW YORK (AP) -- A Cowen & Co. analyst downgraded shares of Baxter International on Wednesday, saying its hemophilia drug Advate faces a greater threat than he had realized. THE OPINION: Analyst ...
A post-hoc analysis has identified an interrelation between peak levels of factor VIII (:FVIII) in a patient’s body in the first few hours after infusion and the efficiency of prophylaxis treatment in ...
A meta-analysis of post-authorization safety studies (:PASS) of the Advate demonstrated that the product lowers inhibitor rate and is safe and effective for use in routine clinical practices. The ...
Baxter International Inc. said Thursday that it will pull back some promotional literature for its new blood-clotting drug after a warning from the U.S. Food and Drug Administration. The ...
Baxter announced that the FDA has approved Advate (antihemophilic Factor VIII [recombinant]) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with ...
Deerfield, Ill., July 25, 2003 -- Baxter Healthcare Corporation announced today that the U.S. Food and Drug Administration (FDA) has approved ADVATE (Antihemophilic Factor (Recombinant), ...
Baxter Reports Results of ADVATE Real-World Experience from Worldwide Post-Marketing Database of Hem
Analyses Presented during ISTH Support ADVATE's 10-year Real-world Experience ''This meta-analysis of the post-market surveillance database, the largest available in hemophilia today, demonstrates a ...
Hemophilia patients in India can now have more treatment options as global biotechnology major Shire on Tuesday announced that doctors in India can now prescribe ADVATE, a widely used treatment for ...
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis ...
Shire plc recently launched ADVATE (Octocog alfa – Recombinant Coagulation Factor VIII) in India for the treatment and prophylaxis of bleeding in patients with haemophilia A ADVATE, which came to ...
ADVATE (antihemophilic factor [recombinant] plasma/albumin-free method) 4000IU for IV use by Baxter Baxter announced that the FDA has approved a new 4000 IU dosage strength of Advate (Antihemophilic ...
Baxter International ( BAX) presented encouraging data from the Advate [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] prophylaxis study at the International Society on Thrombosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results